Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Gastrointestinal 1

Conditions

Stomach Neoplasms 1Melanoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × BO-112 × Clear all
NCT06422936 2026-01-26

SPOTLIGHT204

Highlight Therapeutics

Phase 2 Active not recruiting
60 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT04570332 2025-11-26

SPOTLIGHT203

Highlight Therapeutics

Phase 2 Completed
42 enrolled 12 charts
Dermatologic

Melanoma

NCT04508140 2024-11-29

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Highlight Therapeutics

Phase 2 Terminated
18 enrolled 13 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡